Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial

The Lancet Global Health

Volumn 5, Issue 5, 2017, Pages e491-e500

  Lockman, Shahin ^a,b,c   Hughes, Michael ^c   Powis, Kate ^b,d   Ajibola, Gbolahan ^b   Bennett, Kara ^e   Moyo, Sikhulile ^b   van Widenfelt, Erik ^b   Leidner, Jean ^f   McIntosh, Kenneth ^g   Mazhani, Loeto ^h   Makhema, Joseph ^b   Essex, Max ^b,c   Shapiro, Roger ^b,c,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Bennett Statistical Consulting Inc   (United States)

^f Goodtables Data Consulting   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h UNIVERSITY OF BOTSWANA   (Botswana)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; NEVIRAPINE; PLACEBO; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BOTSWANA; BREAST FEEDING; CHILD; CHILDHOOD MORTALITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MORTALITY; PNEUMONIA; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE DRUG DOSE; ADULT; ANTIBIOTIC RESISTANCE; CHILD DEATH; EPIDEMIOLOGY; ESCHERICHIA COLI; FEMALE; HOSPITALIZATION; NEUTROPENIA; NEWBORN; PERINATAL DEATH; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; VERTICAL TRANSMISSION;

ADULT; ANTI-HIV AGENTS; BOTSWANA; BREAST FEEDING; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INFANT; INFANT DEATH; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEUTROPENIA; PERINATAL DEATH; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85017224761     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(17)30143-2     Document Type: Article

References (46)

1. 1 Wiktor, SZ, Sassan-Morokro, M, Grant, AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 353 (1999), 1469–1475.
2. 2 Anglaret, X, Chene, G, Attia, A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 353 (1999), 1463–1468.
3. 3 Mermin, J, Lule, J, Ekwaru, JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364 (2004), 1428–1434.
4. 4 Chintu, C, Bhat, GJ, Walker, AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 364 (2004), 1865–1871.
5. 5 Bwakura-Dangarembizi, M, Kendall, L, Bakeera-Kitaka, S, et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 370 (2014), 41–53.
6. 6 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization Programme. http://www.who.int/hiv/pub/arv/arv-2016/en/, 2016 (accessed Feb 3, 2017).
7. 7 WHO. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://apps.who.int/iris/bitstream/10665/145719/1/9789241508193_eng.pdf?ua=1, 2014 (accessed Feb 3, 2017).
8. 8 Homsy, J, Dorsey, G, Arinaitwe, E, et al. Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: a randomised controlled open-label trial. Lancet Glob Health 2 (2014), e727–e736.
9. 9 Mbeye, NM, ter Kuile, FO, Davies, MA, et al. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health 19 (2014), 1057–1067.
10. 10 Harouna, AM, Amorissani-Folquet, M, Eboua, FT, et al. Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort study. BMC Infect Dis, 15, 2015, 317.
11. 11 Davis, NL, Barnett, EJ, Miller, WC, et al. Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants. Clin Infect Dis 61 (2015), 368–374.
12. 12 Kapito-Tembo, A, Meshnick, SR, van Hensbroek, MB, Phiri, K, Fitzgerald, M, Mwapasa, V, Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 203 (2011), 464–472.
13. 13 Kamya, MR, Kapisi, J, Bigira, V, et al. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS 28 (2014), 2701–2709.
14. 14 Coutsoudis, A, Kindra, G, Esterhuizen, T, Impact of cotrimoxazole prophylaxis on the health of breast-fed, HIV-exposed, HIV-negative infants in a resource-limited setting. AIDS 25 (2011), 1797–1799.
15. 15 Kourtis, AP, Wiener, J, Kayira, D, et al. Health outcomes of HIV-exposed uninfected African infants. AIDS 27 (2013), 749–759.
16. 16 Thea, DM, St. Louis, ME, Atido, U, A prospective study of diarrhea and HIV-1 infection among 429 Zairian infants. N Engl J Med 329 (1993), 1696–1702.
17. 17 Brahmbhatt, H, Kigozi, G, Wabwire-Mangen, F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 41 (2006), 504–508.
18. 18 Marinda, E, Humphrey, JH, Iliff, PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 26 (2007), 519–526.
19. 19 Newell, ML, Coovadia, H, Cortina-Borja, M, Rollins, N, Gaillard, P, Dabis, F, Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364 (2004), 1236–1243.
20. 20 WHO, United Nations Children's Fund. Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV, 2016, World Health Organization, Geneva.
21. 21 WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach – 2010 version. http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf, 2010 (accessed Feb 3, 2017).
22. 22 WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf?ua=1, 2006 (accessed Feb 3, 2017).
23. 23 National Institutes for Health. Division of AIDS table for grading the severity of adult and pediatric adverse events. https://rsc.tech-res.com/clinical-research-sites/safety-reporting/daids-grading-tables, December, 2004 (accessed Feb 1, 2017).
24. 24 CLSI. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement M100-S19, 2009, Clinical and Laboratory Standards Institute, Wayne, PA.
25. 25 Thior, I, Lockman, S, Smeaton, LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296 (2006), 794–805.
26. 26 Guo, C, So, Y, Johnston, G, Analyzing interval-censored data with the ICLIFETEST procedure. Paper SAS279-2014, 2014, SAS Institute, Cary, NC.
27. 27 Bigira, V, Kapisi, J, Clark, TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med, 11, 2014, e1001689.
28. 28 Nankabirwa, JI, Wandera, B, Amuge, P, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 58 (2014), 1404–1412.
29. 29 Wilen, M, Buwembo, W, Sendagire, H, Kironde, F, Swedberg, G, Cotrimoxazole resistance of Streptococcus pneumoniae and commensal streptococci from Kampala, Uganda. Scand J Infect Dis 41 (2009), 113–121.
30. 30 Mwenya, DM, Charalambous, BM, Phillips, PP, et al. Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob Agents Chemother 54 (2010), 3756–3762.
31. 31 Marwa, KJ, Mushi, MF, Konje, E, Alele, PE, Kidola, J, Mirambo, MM, Resistance to cotrimoxazole and other antimicrobials among isolates from HIV/AIDS and Non-HIV/AIDS patients at Bugando Medical Centre, Mwanza, Tanzania. AIDS Res Treat, 2015, 2015, 103874.
32. 32 Malamba, SS, Mermin, J, Reingold, A, et al. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg 75 (2006), 375–380.
33. 33 Pressiat C, Benaboud S, Treluyer JM, et al. Population pharmacokinetics of cotrimoxazole West African HIV-infected children. 22nd Conference on Retroviruses and opportunistic Infections; Seattle, WA, USA; Feb 23–26, 2015. Abstract 512.
34. 34 Shapiro, RL, Lockman, S, Kim, S, et al. Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis 196 (2007), 562–569.
35. 35 Zash R, Leidner J, Souda S, et al. HIV-Exposed children account for more than half of 24-month mortality in Botswana. 23rd Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 22–25, 2016. Abstract 802.
36. 36 Berglund, A, Ekelund, M, Fletcher, MA, Nyman, L, All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction. PLoS One, 9, 2014, e112211.
37. 37 Suarez, V, Michel, F, Toscano, CM, et al. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: time series analyses. Vaccine 34 (2016), 4738–4743.
38. 38 Gastanaduy, PA, Steenhoff, AP, Mokomane, M, et al. Effectiveness of monovalent rotavirus vaccine after programmatic implementation in Botswana: a multisite prospective case-control study. Clin Infect Dis 62:suppl 2 (2016), S161–S167.
39. 39 Enane, LA, Gastanaduy, PA, Goldfarb, DM, et al. Impact of rotavirus vaccination on hospitalizations and deaths from childhood gastroenteritis in Botswana. Clin Infect Dis 62:suppl 2 (2016), S168–S174.
40. 40 Silverman, WA, Andersen, DH, Blanc, WA, Crozier, DN, A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 4 (1956), 614–625.
41. 41 Wells, J, Shetty, AK, Stranix, L, et al. Range of normal neutrophil counts in healthy zimbabwean infants: implications for monitoring antiretroviral drug toxicity. J Acquir Immune Defic Syndr 42 (2006), 460–463.
42. 42 Mwinga, K, Vermund, SH, Chen, YQ, et al. Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol. BMC Pediatr, 9, 2009, 49.
43. 43 Kourtis, AP, Bramson, B, van der Horst, C, et al. Low absolute neutrophil counts in African infants. J Int Assoc Physicians AIDS Care (Chic) 4 (2005), 73–76.
44. 44 Nielsen-Saines, K, Watts, DH, Veloso, VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 366 (2012), 2368–2379.
45. 45 WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, 2010 (accessed Feb 3, 2017).
46. 46 Shapiro, RL, Hughes, MD, Ogwu, A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362 (2010), 2282–2294.